LifeStance Health Group (LFST) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LifeStance Health Group in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LFST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LFST, but not buy additional shares or sell existing shares.
View LFST analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month target prices for LifeStance Health Group's shares. Their LFST share price targets range from $8.00 to $9.00. On average, they predict the company's stock price to reach $8.60 in the next twelve months. This suggests a possible upside of 50.6% from the stock's current price.
View analysts price targets for LFST or view top-rated stocks among Wall Street analysts.

LifeStance Health Group's stock was trading at $7.83 at the start of the year. Since then, LFST stock has decreased by 27.1% and is now trading at $5.71.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our LFST earnings forecast.

LifeStance Health Group will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

LifeStance Health Group, Inc. (NASDAQ:LFST) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.03. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $263.14 million. LifeStance Health Group had a negative trailing twelve-month return on equity of 12.66% and a negative net margin of 17.64%.

ETFs with the largest weight of LifeStance Health Group (NASDAQ:LFST) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC) and First Trust Small Cap Growth AlphaDEX Fund (FYC).iShares U.S. Healthcare Providers ETF (IHF).

LifeStance Health Group updated its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $287.0 million-$307.0 million, compared to the consensus revenue estimate of $299.1 million.

LifeStance Health Group (LFST) raised $640 million in an initial public offering on Thursday, June 10th 2021. The company issued 40,000,000 shares at $15.00-$17.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan, Jefferies, TPG Capital BD LLC, UBS Investment Bank and William Blair acted as the underwriters for the IPO and Capital One Securities, AmeriVet, Drexel Hamilton, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

LifeStance Health Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include O Brien Wealth Partners LLC (0.14%). Insiders that own company stock include Anisha Patel-Dunn, Ann Varanakis, Danish J Qureshi, David Bourdon, Gwen H Booth, Jeffrey Crisan, Jesse Michael Bruff, Kenneth T Mills, Kevin Michael Mullins, Michael K Lester, Paula Cipollone, Ryan Pardo, Silversmith Partners I Gp, Llc, Summit Partners Growth Equity and Warren Gouk.
View institutional ownership trends.

Shares of LFST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.